FDMT - 4D Molecular Therapeutics, Inc.

QQQ $ 441.71 $ 1.04 (0.24 %)

DIA $ 395.04 $ 1.18 (0.3 %)

SPY $ 520.76 $ 0.67 (0.13 %)

TLT $ 90.14 $ -0.51 (-0.56 %)

GLD $ 218.73 $ 1.76 (0.81 %)

Previous Close

$ 25.7

Open

$ 26.24

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 24.33 - $ 26.24

52 Week Range

$ 9.44 - $ 36.25

Volume

397,446

Average Volume

Market Cap

1.27B

Beta (5Y Monthly)

$ 1.80

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	02-29-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-09-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	03-15-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-28-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-13-2021	03-31-2021	10-Q
14	03-25-2021	12-31-2020	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

4D Molecular Therapeutics Q1 2024 GAAP EPS...
05/09/2024 21:16:02

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimat...

to-the-moon-a-look-inside-an-etf-focused-on-companies-at-the-cutting-edge-of-innovation

To The Moon! A Look Inside An ETF Focused ...
04/18/2024 18:29:09

RBC Capital Maintains Outperform on 4D Mol...
04/15/2024 17:13:54

RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price targe...

Barclays Initiates Coverage On 4D Molecula...
04/15/2024 11:06:38

Barclays analyst Gena Wang initiates coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight rating and announ...

BMO Capital Maintains Outperform on 4D Mol...
04/01/2024 16:18:10

BMO Capital analyst Kostas Biliouris maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and lowers the pric...

Jefferies Maintains Buy on 4D Molecular Th...
04/01/2024 14:49:55

Jefferies analyst Nalin Tejavibulya maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target...

4d-molecular-therapeutics-outlines-pivotal-development-plans-for-cystic-fibrosis-rare-inherited-disease

4D Molecular Therapeutics Outlines Pivotal...
03/28/2024 18:04:07

4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine...

4DMT Announces Update On Regulatory Intera...
03/28/2024 12:10:24

Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EM...

4D Molecular Therapeutics Stock: A Deep Di...
03/01/2024 13:01:13

HC Wainwright & Co. Reiterates Buy on 4D M...
03/01/2024 12:35:20

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains...

4DMT FY23 EPS $(2.58) Vs $(3.32) YoY
02/29/2024 21:35:04

Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD p...

4DMT Presents Interim Data From 4D-310 ING...
02/12/2024 13:10:54

4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography...

why-is-blindness-focused-adverum-biotechnologies-stock-trading-lower-today

Why Is Blindness Focused-Adverum Biotechno...
02/08/2024 19:59:21

Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and s...

why-4d-molecular-therapeutics-fdmt-stock-is-diving

Why 4D Molecular Therapeutics (FDMT) Stock...
02/07/2024 19:56:29

4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized un...

What 4 Analyst Ratings Have To Say About 4...
02/07/2024 13:00:49

Goldman Sachs Reinstates Buy on 4D Molecul...
02/07/2024 12:17:32

Goldman Sachs analyst Salveen Richter reinstates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and announces $81 price ...

4D Molecular Therapeutics Prices Upsized P...
02/07/2024 06:17:29

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full...

4d-molecular-therapeutics-4d-150-phase-2-data-met-investor-expectations-analyst-boosts-forecast

4D Molecular Therapeutics' 4D-150 Phase 2 ...
02/06/2024 19:05:36

4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.

4D Molecular Therapeutics Files For Mixed ...
02/05/2024 21:41:59

4D Molecular Therapeutics Announces $250M ...
02/05/2024 21:16:18

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a leading clinical-stage genetic medicines company focused on unlocking the full...